Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

AppTrim - A Healthy Way to Manage Appetite and Obesity


Published on

AppTrim® is a medical food manufactured in a cGMP certified facility in the United States, that is specially formulated to manage the increased nutritional requirements of obesity. AppTrim provides the specific amino acids and nutrients required by the body to stimulate the production of key neurotransmitters responsible for controlling appetite, hunger and satiety. AppTrim is clinically proven to reduce appetite, carbohydrate cravings and weight when used in addition to a daily exercise and nutrition plan

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

AppTrim - A Healthy Way to Manage Appetite and Obesity

  1. 1. AppTrim® For the dietary management of obesity.
  2. 2. Providing Patients with a Safer & More Effective Way to Manage Obesity
  3. 3. 03 AppTrim® A Healthy Way to Manage Obesity u Patented Technology Ingredient technology that improves the uptake and conversion of amino acids to neurotransmitters. Decreased Appetite Improving amino acid levels can help control hunger and cravings. Safe & Effective Clinically proven ingredients that are Generally Recognized as Safe. Amino Acids The fuel the nervous system needs to communicate efficiently. Improve BMI Decreasing the daily caloric intake can help decrease BMI. Order Today To register an online ordering account please visit:
  4. 4. 04 AppTrim® Decreased Appetite in Double-Blind Study 3.52 3.323.32 3.28 3.15 3.2 3.25 3.3 3.35 3.4 3.45 3.5 3.55 AppTrim Placebo AppetiteIndex Baseline Six Weeks In one double-blind, placebo controlled study*, patients taking AppTrim twice daily for six weeks experienced a significant reduction in appetite when compared to placebo. * Targeted Medical Pharma; P-105 study; A double-blind placebo controlled trial on the effect of AppTrim on Appetite Suppression and Obesity Management; 2011
  5. 5. 05 AppTrim® Reduction of Body Weight at 6 Weeks Placebo AppTrim In one double-blind, placebo controlled study*, weight loss occurred gradually over a 6 week period in the AppTrim group compared to placebo. Losses averaged 0.5-1 lb/week, consistent with a healthy rate of weight loss. * Targeted Medical Pharma; P-105 study; A double-blind placebo controlled trial on the effect of AppTrim on Appetite Suppression and Obesity Management; 2011 -4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5 0 Baseline Week 2 Week 4 Week 6 WeightLoss(lbs)
  6. 6. 06 The Distinct Amino Acid Requirements of Obesity Connecting Nutrition to Medicine Recent studies focusing on amino acids and neurotransmitters have consistently revealed disruption of normal amino acid metabolism in obese, insulin-resistant states and Type 2 diabetes.* *Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH, “Plasma Metabolomic Profiles Reflective of Glucose Homeostasis in Non-diabetic and Type 2 Diabetic Obese African-American Women” PLoS ONE 2010;5:e15234
  7. 7. 07 AppTrim® Amino Acid Requirements of Obesity Neurotransmitters are prevalent in the stomach and act as important mediators of hunger and satiety. They are responsible for conveying information to regions of the brain that regulate energy balance.* Imbalance of certain neurotransmitters will impact weight regulation, appetite and satiety. Neurotransmitters and their amino acid precursors control appetite, satiety, and carbohydrate cravings. Obese patients often lack appropriate levels of amino acids and neurotransmitters that are responsible for controlling appetite, satiety and carbohydrate cravings.** Increasing the availability of certain amino acids is critical to increasing neurotransmitter production, helping to control appetite and regulate body weight more effectively. *Bray, GA “Medical treatment of obesity: the past, the present and the future” Best Pract. Res Clin Gastroenterol. 2014 Aug; 28 (4): 665-84 **Wurtman RJ, Wurtman, JJ “Brain Serotonin, carbohydrate-craving, obesity and depression” Obesity Research Nov 1995 vol 3, Issue S4 pg 477S-480S
  8. 8. 08 As a medical food, AppTrim addresses specific amino acid deficiencies associated with obesity. Addressing the increased amino acid requirements of obesity can help coordinate communication between the brain, stomach and nervous system helping to reduce appetite quicker and for a longer period of time. AppTrim is an important part of an Obesity management program and is a safe and effective tool for reducing appetite, BMI and managing obesity. Amino Acids and Appetite Control Appetite and Satiety with Targeted Nutrition Amino acids and neurotransmitters, particularly serotonin and dopamine, play a key role in regulating appetite. It has been observed that low serotonin and dopamine levels trigger carbohydrate cravings and increased consumption of calories.
  9. 9. PRECAUTIONS AND CONTRAINDICATIONS AppTrim is contraindicated in an extremely small number of patients with hypersensitivity to any of the nutritional components of AppTrim. ADVERSE REACTIONS Ingestion of L-Tryptophan or Choline at high doses of up to 15 grams daily is generally well tolerated. The most common adverse reactions of higher doses — from 15 to 30 grams daily — are nausea, abdominal cramps, and diarrhea. AppTrim contains less than 1 gram per dose of amino acids however, some patients may experience these symptoms at lower doses. The total combined amount of amino acids in each AppTrim capsule does not exceed 300 mg. DRUG INTERACTIONS AppTrim does not directly influence the pharmacokinetics of prescription drugs. Clinical experience has shown that administration of AppTrim may allow for lowering the dose of co-administered drugs under physician supervision. OVERDOSE There is a negligible risk of overdose with AppTrim as the total amount of amino acids in a one month supply (120 capsules) is less than 30 grams. Overdose symptoms may include diarrhea, weakness, and nausea. 09 Safety Information
  10. 10. 1. Kaidar-Person Orit; Person Benjamin; Szomstein Samuel; Rosenthal Raul J. “Nutritional Deficiencies in Morbidly Obese Patients: A New Form of Malnutrition Part A: Vitamins. Obesity Surgery 2008, vol. 18 No. 7 pp. 870-876 2. Toh SY, Zarshenas N, Jorgensen J. “Prevalence of Nutrient Deficiencies in Bariatric Patients” Nutrition 2009; 25(11-12): 150-6 3. Moize V, Deulofeu R, Torres F, de Ossaba JM, Vidal J. “Nutritional Intake and Prevalence of Nutritional Deficiencies Prior to Surgery in a Spanish Morbidly Obese Population” Obes Surg 2011; 21(9): 1382-8 4. Antje Damms-Machado, Gesine Weser, Stephan C. Bischoff, “Micronutrient Deficiency in Obese Subjects Undergoing low calorie diet” Nutr J. 2012; 11:34 5. Balthasar N, Dalgaard LT, Lee CE, Yu J, Fumahashi H, Williams T, Ferreira M, Tang V, McGovern RA, Kenny CD, et al. “Divergence of Melanocortin Pathways in the Control of Food Intake and Energy Expenditure” Cell 2005; 123:493-505 6. Xu Y, Tong Q. “Expanding Neurotransmitters in the hypothalamic Neurocircuitry for Energy Balance Regulation” Protein Cell 2011; 2:800-813 7. Kabadi Shaum, Lui Longjian, “Increased Risk for Diabetes when Obesity and Low Vitamin D are Present” Diabetes Care 8. Adams, Sean “Emerging Perspectives on Essential Amino Acid Metabolism in Obesity and the Insulin-Resistant State” Adv Nutr Nov 2011 vol. 2: 445-456 9. Menge BA, Schrader H, Ritter PR, Ellrichmann M, Uhl W, Schmidt WE, Meier JJ “”Selective Amino Acid Deficiency in Patients with Impaired Glucose Tolerance and Type 2 Diabetes” Regul Pept 2010 Feb 25; 160 (1-3): 75-80 10. McClung JP, Karl JP “Iron Deficiency and Obesity: the Contribution of Inflammation and Diminished Iron Absorption” Nutr Rev. 2009; 67:100-104 11. Dibaise, JK, Frank, DN, Mathur, R “Impact of the gut microbiota on the development of obesity: current concepts” Am J Gastroenterol Suppl (2012) 1:22-27 12. Collado MC, Isolauri E, Laitinen K et al. “Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women” Am J Clin Nutr 2008; 88: 894- 899 13. Meister B. “Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight” Physiol Behav 2007; 92: 263-271 14. Breum L, Rasmussen MH, Hilsted J, Fernstrom JD “Twenty four hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction” Am J Clin Nutr 2003 May; 77(5): 1112-8 15. Fernstrom MH “Depression, antidepressants, and body weight” Ann Ny Acad Sci 1989; 575: 31- 40 16. Wurtman RJ, Wurtman, JJ “Brain Serotonin, carbohydrate-craving, obesity and depression” Obesity Research Nov 1995 vol 3, Issue S4 pg 477S-480S 17. Reinholz J, Skopp O, Breitenstein, C, Bohr I, Wiinterhoff H, Knecht S “Compensatory weight gain due to dopaminergic hypofucntion: new evidence and own incidental observations” Nutrition & Metabolism 2008, 5:35 10 Selected References What Does the Science Say?
  11. 11. 12 For More Information WWW.TMEDPHARMA.COM